Ryan Santin
Psychiatry · Lincoln, NENPI 1649698523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.5% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 26.6% of the total. 2025 is the largest year on record at $1,270, more than ten times the $115 reported in 2023.
Across 121 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$542
- Neurocrine Biosciences, Inc.$278
- E.r. Squibb & Sons, L.L.C.$153
- Otsuka America Pharmaceutical, Inc.$129
- Alkermes, Inc.$128
- Johnson & Johnson$116
- plus $690 from 19 others
What the payments were for
- Food & beverage$1,92595%
- Education$1115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 31 | $542 |
| Neurocrine Biosciences, Inc. | 17 | $278 |
| E.r. Squibb & Sons, L.L.C. | 16 | $153 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Alkermes, Inc. | 5 | $128 |
| Johnson & Johnson | 7 | $116 |
| Vertex | 4 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $63 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $49 |
| AbbVie | 2 | $45 |
| AstraZeneca | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Exact Sciences | 2 | $33 |
| Novo Nordisk | 2 | $31 |
| Lilly USA, LLC | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Amgen | 1 | $26 |
| Abbott | 1 | $25 |
| Mylan Specialty L.p. | 1 | $20 |
| Bayer | 1 | $17 |
| Indivior Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$2,036 in reported general payments places this provider in the 80th percentile of 160 psychiatry providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 37 | $128,200 |
| IngrezzaValbenazine Tosylate | 21 | $120,588 |
| VraylarCariprazine Hcl | 13 | $27,428 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $24,483 |
| Lurasidone Hcl | 62 | $6,289 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,647 |
| Clozapine | 120 | $3,225 |
| Bupropion XlBupropion Hcl | 149 | $2,940 |
| Atomoxetine Hcl | 31 | $2,535 |
| Duloxetine Hcl | 129 | $2,389 |
| Buprenorphine | 17 | $2,367 |
| Trazodone Hcl | 161 | $1,825 |
| Lamotrigine | 97 | $1,796 |
| Olanzapine | 83 | $1,688 |
| Gabapentin | 101 | $1,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $116 | $128,20037 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $278 | $120,58821 claims |
| AbbVieVraylar | $45 | $27,42813 claims |
| Alkermes, Inc.Lybalvi | $128 | $24,48315 claims |
| Lilly USA, LLCOlanzapine | $31 | $1,68883 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 160 psychiatry providers in Nebraska.
Other psychiatry in Lincoln
- Walter DuffyLincoln$46K
- Dianna ClyneLincoln$19K
- Jeffrey CoffmanLincoln$18K
- Kelli BremerLincoln$13K
- Rajeev ChaturvediLincoln$6K
- Danielle BudaLincoln$5K
- Andi NgoLincoln$1K
- Jessica BuettnerLincoln$1K
- Sanat RoyLincoln$794
- William MichaelLincoln$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.